Pharmaceutical company Allergan said it reached an agreement with InnoPharma Inc. resolving patent litigation regarding six patents covering its dry eye drug Restasis (Cyclosporine Ophthalmic Emulsion) 0.05%.
The patents are listed in the Orange Book and expire on August 27, 2024.
“As a result of the settlement, all InnoPharma Hatch-Waxman litigation regarding Restasis patents will be dismissed,” said Allergan.
“Pursuant to the terms of the settlement, Allergan will grant InnoPharma licenses to market a generic version of Restasis in the United States beginning on February 24, 2024, or earlier under certain circumstances.
“Additionally, under certain circumstances, Allergan will supply and authorize InnoPharma to launch an authorized generic version of Restasis on August 28, 2024.”